Organigram schedules 2026 digital investor session
Organigram Global Inc. opened registration for its September 30, 2026 digital investor session focused on global cannabis growth plans.
Rhea-AI Filing Summary
Organigram Global Inc. (OGI) announced that registration is open for its 2026 OG Investor Session, a digital investor event focused on the company’s global growth strategy. The session will premiere on September 30, 2026 at 4:00 p.m. ET as a video presentation featuring senior leadership, including CEO James Yamanaka, CFO Greg Guyatt and Finn Age Hänsel, President, Rest of World & CSO. The program is expected to cover growth initiatives, strategic priorities, and insights from team members across Organigram’s Canadian and European cannabis operations, followed by a fireside Q&A with investor-submitted questions. Organigram highlights its position as Canada’s #1 cannabis company by market share, its acquisition of Sanity Group GmbH to access the German and broader European medical cannabis markets, and its portfolio of brands and production facilities across multiple Canadian provinces.
Positive
- None.
Negative
- None.
Key Figures
Investor session premiere date: September 30, 2026
Investor session time: 4:00 p.m. ET
Listing venues: NASDAQ Global Select Market and TSX
3 metrics
Investor session premiere date
September 30, 2026
Date of the 2026 OG Investor Session video presentation
Investor session time
4:00 p.m. ET
Scheduled start time for the 2026 OG Investor Session premiere
Listing venues
NASDAQ Global Select Market and TSX
Equity listing venues for Organigram Global Inc.
Key Terms
forward-looking information, licensed cultivator and processor, Cannabis Regulations, digital investor session, +1 more
5 terms
forward-looking information regulatory
"This news release contains forward-looking information."
Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.
licensed cultivator and processor regulatory
"Organigram Inc., a licensed cultivator and processor."
Cannabis Regulations regulatory
"regulated by Health Canada under the Cannabis Act and the Cannabis Regulations."
digital investor session financial
"the Company's second Digital Investor Session, featuring updates"
medical cannabis market medical
"participates in the German medical cannabis market and other emerging markets"
FAQ
What did OGI announce in this Form 6-K?
Organigram Global Inc. announced details of its 2026 OG Investor Session, a digital investor event featuring leadership presentations, strategic updates on global cannabis growth, operational insights from facilities, and a fireside Q&A using investor-submitted questions.
When will Organigram Global’s 2026 OG Investor Session take place?
The 2026 OG Investor Session will premiere on September 30, 2026 at 4:00 p.m. ET as a video presentation, with executive leadership updates, operational insights, and a fireside question-and-answer session with management.
How can investors register for Organigram Global’s 2026 OG Investor Session?
Registration is now open at www.organigram.ca/investor-day-2026. Registrants can submit questions in advance for the fireside chat and will receive updates from Organigram Global Inc. leading up to and following the event.
Who will present at Organigram Global’s 2026 OG Investor Session?
Presenters are expected to include CEO James Yamanaka, CFO Greg Guyatt, and Finn Age Hänsel, President, Rest of World & CSO, along with insights from Organigram team members across its production facilities.
What strategic areas will OGI cover during the 2026 OG Investor Session?
Organigram plans to discuss growth initiatives and strategic priorities, including how it is aligning the business to maintain leadership in Canada and pursue opportunities in global cannabis markets, supported by its Canadian operations and its Sanity Group acquisition in Europe.
What markets and brands does Organigram Global Inc. currently focus on?
Organigram participates in Canadian adult-use and German medical cannabis and other European markets, with brands such as Edison, SHRED, Monjour, BOXHOT, DEBUNK and European brands including Vayamed, avaay, ZOIKS, Endosane Pharmaceuticals, VAAY and Grashaus Projects.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number: 001-38885
ORGANIGRAM GLOBAL INC.
(Translation of registrant’s name into English)
145 King Street West, Suite 1400
Toronto, Ontario ,Canada M5H 1J8
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [ X ]
SUBMITTED HEREWITH
Exhibits
99.1 | News Release dated September 2, 2026 | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ORGANIGRAM GLOBAL INC.
/s/ Greg Guyatt
Greg Guyatt
Chief Financial Officer
Date: September 2, 2026
Organigram Global to Host 2026 OG Investor Session
Registration now open for the Company's second Digital Investor Session, featuring updates from senior leadership on Organigram's global growth strategy
TORONTO, Ontario, September 2, 2026 (BUSINESS WIRE) - Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform, today announced details of its 2026 OG Investor Session.
“Since our last investor session, we’ve welcomed a new leadership team, completed our first full quarter with Sanity Group, and sharpened our strategy for the years ahead. We look forward to updating our stakeholders on how we’re aligning Organigram to build on our leadership in Canada and capture growth opportunities across global cannabis markets,” said James Yamanaka, Chief Executive Officer.
This year's session will premiere on September 30 at 4:00 p.m. ET as a video presentation and is expected to include:
•Presentations from executive leadership, including CEO James Yamanaka, CFO Greg Guyatt and Finn Age Hänsel, President, Rest of World & CSO;
•Insights from Organigram team members across its production facilities;
•Discussions on growth initiatives and strategic priorities; and
•A fireside question-and-answer session with management, featuring investor-submitted questions.
Registration and Q&A Submission
Registration is now open at www.organigram.ca/investor-day-2026. Registrants can submit questions for the fireside chat ahead of the premiere and will receive updates from the Company leading up to and following the event.
ABOUT ORGANIGRAM
Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiaries include Organigram Inc., a licensed cultivator and processor. Through its acquisition of Sanity Group GmbH ("Sanity Group"), Organigram participates in the German medical cannabis market and other emerging markets within Europe.
Organigram is focused on producing high-quality cannabis for adult consumers, as well as extending the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Through its acquisition of Sanity Group, Organigram's European brands include Vayamed, avaay, ZOIKS, Endosane Pharmaceuticals, VAAY, and Grashaus Projects. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.
FORWARD-LOOKING INFORMATION
This news release contains forward-looking information. Often, but not always, forward looking information can be identified by the use of words such as "plans", "expects", “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information including expectations regarding market performance, involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and the risks disclosed in the Company’s most recent annual information form, management’s discussion and analysis, and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
FOR INVESTOR RELATIONS ENQUIRIES
Max Schwartz, Director of Investor Relations
investors@organigram.ca
FOR MEDIA RELATIONS ENQUIRIES
Mark McKay, Director of Communications